Medical Device | May 20, 2026
Boston Scientific invests $1.5 billion in MiRus for TAVR expansion
Deal includes exclusive option to acquire MiRus’ SIEGEL TAVR system for an additional $3 billion upon milestone achievements
Deal includes exclusive option to acquire MiRus’ SIEGEL TAVR system for an additional $3 billion upon milestone achievements
By leveraging digital screening and remote consultation, the medical community is moving beyond the confines of the clinic
The development comes as stroke remains one of the world’s biggest health threats
Discussions during the meeting focused on strengthening India’s preparedness against zoonotic diseases and climate-sensitive health challenges
Deployment aims to improve serialization efficiency by 45% and enhance regulatory compliance across global export markets
The next-generation proteomics platform powered by Olink™ Explore HT enables simultaneous analysis of thousands of proteins from a single sample
The country’s strength lies not just in technology availability but in adoption behaviour
The drug also delivered a disease control rate (DCR) of 83.3% in high-dose cohorts and a mean progression-free survival of 6.3 months in SCLC patients
Despite the strong results, investigators cautioned that the study has limitations, including its open-label Phase II design, lack of randomization, and reliance on a historical external control arm
AstraZeneca highlighted the move as a major step toward earlier intervention in curable disease
Subscribe To Our Newsletter & Stay Updated
